Annexon, Inc. is a biopharmaceutical company developing targeted immunotherapies for complement-mediated neuroinflammatory diseases affecting the body, brain, and eye. The company focuses on inhibiting the classical complement pathway by targeting C1q, the initiating molecule of the cascade. Its pipeline includes tanruprubart, an investigational therapy for Guillain-Barré Syndrome, and vonaprument, a neuroprotective inhibitor for geographic atrophy associated with dry age-related macular degeneration. Additionally, the company is developing ANX1502, a novel oral small molecule inhibitor of C1s for autoimmune conditions. Annexon was co-founded in 2007 by Dr. Ben Barres and Dr. Arnon Rosenthal. The company holds worldwide development and commercialization rights to its product candidates and has established regulatory pathways with the FDA and EMA.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage annexonbio.com
Sector Healthcare IR page ir.annexonbio.com/contact-ir
Tags
complement-mediated diseases, neuroinflammation, autoimmune disorders, neurodegeneration, ophthalmology, guillain-barré syndrome, geographic atrophy, targeted immunotherapy, c1q inhibitors, small molecule drugs, tanruprubart, vonaprument, ANX1502, ANX005, ANX007, ANX009
Press page —

Metrics

Valuation  
Market cap $ 865.681M
Market cap (USD) $ 865.681M
P/E -4.15
PEG —
P/BV 6.06
P/S —
P/OCF -4.57
P/FCF -4.57
Dividend yield —
Turnover / mcap —
Returns  
ROE -81.9%
ROI -283.6%
ROIC -222.7%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 34.6%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 34
Quality score -75.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Assets 277.571M 350.071M 297.674M 285.096M 287.04M 355.946M 49.898M
Net profit -206.69M -138.2M -134.237M -141.947M -130.323M -63.412M -37.183M
Free cash flow -186.493M -118.021M -121.335M -122.835M -107.764M -53.551M -28.625M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 5.02 5.13 4.54 5.17 11.49 25.03 —
Price performance 12m -0.02 0.13 -0.12 -0.55 -0.54 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, non-current (USD) — — — — — — — 0.00
Lease liabilities (USD) — — — 34.6M 32.9M 31.4M 29M 26.2M
Cash and deposits (USD) 44.2M 43.9M 269M 74.8M 140M 225M 49.5M 162M
Right-of-use assets (USD) — — — 20.3M 19.1M 18M 16.7M 15.2M
Net debt (borrowings + leases - cash) (USD) — — — — — — — -136M
Cash flow detail
Operating cash flow (USD) — -28.4M -53.1M -106M -116M -121M -118M -186M
Purchases of property, plant and equipment (USD) — -267,000 -464,000 -1.65M -6.53M -193,000 -15,000 -137,000
Change in payables (cash effect) (USD) — 931,000 1.51M 3.86M -287,000 -2.08M 4.94M 4.49M
Income taxes paid (cash effect) (USD) — -2,000 — — — — — —
Share-based compensation (USD) — 2.04M 4.89M 16.3M 18.5M 18.2M 19.4M 16.4M
Free cash flow (OCF - PPE - intangibles) (USD) — -28.6M -53.6M -108M -123M -121M -118M -186M
Income detail
Research and development expense (USD) — 24.5M 49.3M 100M 113M 114M 119M 185M
↳ 5y CAGR +37.3% +30.2%
Total comprehensive income (USD) — -37.2M -63.4M -130M -142M -134M -138M -207M
Comprehensive income to owners (USD) — -37.2M -63.4M -130M -142M -134M -138M -207M
Reported Sep 8, 2020 Mar 25, 2021 Mar 25, 2021 Mar 1, 2022 Mar 6, 2023 Mar 26, 2024 Mar 3, 2025 Nov 9, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Differentiated C1q Platform Advances Two Registrational Programs with Blockbuster Potential, Driving Near-Term Value Catalysts

Tanruprubart U.S./EU FORWARD Data in GBS Strengthens BLA Submission Package Anticipated in Q4 2026; Tanruprubart EU MAA Currently Under Review

Vonaprument ARCHER II Phase 3 Well-Designed to Demonstrate Clinically Meaningful Vision Protection in GA; Month 15 Primary Endpoint Assessment on Track for Q4 2026

ANX1502 Data Support Continued Development of Potential First Oral C1s Inhibitor for Autoimmune Diseases, including gMG; Tablet Formulation Optimization Underway

Cash, Cash Equivalents and Short-Term Investments of $213 Million as of September 30, 2026, Provide Anticipated Runway into 2028

BRISBANE, Calif., November 9, 2026 – Annexon, Inc. (Nasdaq: ANNX) a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact approximately 10 million people worldwide, today highlighted portfolio progress, announced key anticipated milestones, and reported third quarter 2026 financial results.

October 28, 2026 at 8:01 AM EDT

PDF Version

BRISBANE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it will host a virtual investor event on Tuesday, November 3, 2026 at 11:00 AM ET regarding the ARCHER II Phase 3 program. To register, click here.

Company management will highlight the Phase 3 ARCHER II clinical trial design, patient demographics and communication strategy for the anticipated 15-month and 24-month results beginning in Q4 2026. The Company will also highlight the recent strengthening of its Ophthalmology team.

The event will feature Roger Goldberg, MD, MBA (Bay Area Retina Associates and ARCHER II Clinical Investigator), who will join company management to discuss the unmet need and current treatment landscape for geographic atrophy (GA), the advanced form of dry, age-related macular degeneration (AMD) of the retina.

A live question and answer session will follow the formal presentations.

About Roger A. Goldberg, MD, MBA Roger A. Goldberg, MD, MBA, a native of Boston, graduated from both college and medical school at Yale University. He completed his residency in Miami at the Bascom Palmer Eye Institute, the nation’s top eye hospital and residency-training program. He returned to Boston for a fellowship in Vitreoretinal Diseases and Surgery at Tufts and Ophthalmic Consultants of Boston. Dr. Goldberg is board certified by the American Board of Ophthalmology and is an active member of the American Society of Retinal Specialists, the Retina Society, and the American Academy of Ophthalmology. Dr. Goldberg has published numerous research manuscripts and book chapters, including first-author publications in The New England Journal of Medicine, Ophthalmology, JAMA Ophthalmology, and American Journal of Ophthalmology. His surgical interests include macular surgery, complex retinal detachment repair and complications of cataract surgery.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:

Joyce Allaire LifeSci Advisors [email protected]

Media Contact: Christian Vaughn [email protected]

Print

IR Contact

RSS Feeds

Email Alerts

October 16, 2026 at 5:35 PM EDT

PDF Version

BRISBANE, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to six new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on October 7, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the six new non-executive employees received options to purchase 1,270,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to $3.60, which was the closing price of Annexon’s common stock on October 15, 2026, the date of grant, and vest over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to each employee’s continued service through the applicable vesting dates.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:

Joyce Allaire LifeSci Advisors [email protected]

Print

IR Contact

RSS Feeds

Email Alerts

Prompts

Annexon, Inc. (ticker ANNX), listed in United States.

ETFs Holding Annexon, Inc.

ETF Weight in ETF Shares Market value As of
FMED 0.23% 24,000 $ 118.56K Aug 31, 2026
SEIS 0.14% 139,764 $ 798.052K Jun 30, 2026
RUSC 0.11% 15,876 $ 90.652K Jun 30, 2026
FSEG 0.11% 1,064 $ 6,075.44 Jun 30, 2026
FFSM 0.11% 311,203 $ 1.586M Jul 31, 2026
VFMO 0.10% 381,130 $ 1.883M Aug 31, 2026
FSEV 0.09% 1,055 $ 6,024.05 Jun 30, 2026
FESM 0.07% 709,636 $ 4.052M Jun 30, 2026
FEAC 0.05% 2,379 $ 13.584K Jun 30, 2026
TMED 0.05% 2,087 $ 11.917K Jun 30, 2026
RESM 0.03% 166 $ 947.86 Jun 30, 2026
DFAS 0.01% 764,854 $ 3.036M Nov 12, 2026
MSSM 0.01% 8,941 $ 44.169K Aug 31, 2026
DFAC 0.00% 433,698 $ 1.722M Nov 12, 2026
DCOR 0.00% 162,582 $ 645.451K Nov 12, 2026
DFUS 0.00% 49,333 $ 195.852K Nov 12, 2026
DFAU 0.00% 19,704 $ 78.225K Nov 12, 2026